Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 5/2009

01-03-2009 | Original Article

Fibromyalgia subgroups: profiling distinct subgroups using the Fibromyalgia Impact Questionnaire. A preliminary study

Authors: Juliana Barcellos de Souza, Philippe Goffaux, Nancy Julien, Stephane Potvin, Jacques Charest, Serge Marchand

Published in: Rheumatology International | Issue 5/2009

Login to get access

Abstract

The main goal of this project was to identify the presence of fibromyalgia (FM) subgroups using a simple and frequently used clinical tool, the Fibromyalgia Impact Questionnaire (FIQ). A total of 61 women diagnosed with FM participated in this study. FM subgroups were created by applying a hierarchical cluster analysis on selected items of the FIQ (pain, fatigue, morning tiredness, stiffness, anxiety and depressive symptoms). We also tested for group differences on experimental pain, psychosocial functioning and demographic characteristics. Two cluster profiles best fit our data. FM-Type I was characterized by the lowest levels of anxiety, depressive and morning tiredness symptoms, while FM-Type II was characterized by elevated levels of pain, fatigue, morning tiredness, stiffness, anxiety and depressive symptoms. Both FM subgroups showed hyperalgesic responses to experimental pain. These results suggest that pain and stiffness are universal symptoms of the disorder but that psychological distress is a feature present only in some patients.
Literature
1.
Wolfe F, Smythe HA, Yunus MB et al (1990) The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia Report of the Multicenter Criteria Committee. Arthritis Rheum 33:160–172PubMedCrossRef
2.
Burckhardt CS, Clark SR, Bennett RM (1991) The Fibromyalgia Impact Questionnaire: development and validation. J Rheumatol 18:728–733PubMed
3.
Turk DC, Okifuji A, Sinclair JD, Starz TW (1996) Pain, disability, and physical functioning in subgroups of patients with fibromyalgia. J Rheumatol 23:1255–1262PubMed
4.
Turk DC, Okifuji A, Sinclair JD, Starz TW (1998) Differential responses by psychosocial subgroups of fibromyalgia syndrome patients to an interdisciplinary treatment. Arthritis Care Res 11:397–404PubMedCrossRef
5.
Giesecke T, Williams DA, Harris RE et al (2003) Subgrouping of fibromyalgia patients on the basis of pressure-pain thresholds and psychological factors. Arthritis Rheum 48:2916–2922PubMedCrossRef
6.
Naschitz JE, Rozenbaum M, Rosner I et al (2001) Cardiovascular response to upright tilt in fibromyalgia differs from that in chronic fatigue syndrome. J Rheumatol 28:1356–1360PubMed
7.
Graven-Nielsen T, Aspegren KS, Henriksson KG et al (2000) Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. Pain 85:483–491PubMedCrossRef
8.
Hurtig IM, Raak RI, Kendall SA, Gerdle B, Wahren LK (2001) Quantitative sensory testing in fibromyalgia patients and in healthy subjects: Identification of subgroups. Clin J Pain 17:316–322PubMedCrossRef
9.
Turk DC (2005) The potential of treatment matching for subgroups of patients with chronic pain: lumping versus splitting. Clin J Pain 21:44–55PubMedCrossRef
10.
Muller W, Schneider EM, Stratz T (2007) The classification of fibromyalgia syndrome. Rheumatol Int 27:1005–1010PubMedCrossRef
11.
Robinson ME, Brown JL, George SZ et al (2005) Multidimensional success criteria and expectations for treatment of chronic pain: the patient perspective. Pain Med 6:336–345PubMedCrossRef
12.
Raak R, Hurtig I, Wahren LK (2003) Coping strategies and life satisfaction in subgrouped fibromyalgia patients. Biol Res Nurs 4:193–202PubMedCrossRef
13.
Hamilton NA, Karoly P, Zautra AJ (2005) Health goal cognition and adjustment in women with fibromyalgia. J Behav Med 28:1–12CrossRef
14.
Marques AP, Ferreira EA, Matsutani LA, Pereira CA, Assumpcao A (2005) Quantifying pain threshold and quality of life of fibromyalgia patients. Clin Rheumatol 24:266–271PubMedCrossRef
15.
Perrot S, Dumont D, Guillemin F, Pouchot J, Coste J (2003) Quality of life in women with fibromyalgia syndrome: validation of the QIF, the French version of the Fibromyalgia Impact Questionnaire. J Rheumatol 30:1054–1059PubMed
16.
Kerns RD, Turk DC, Rudy TE (1985) The west Haven-Yale multidimensional pain inventory (WHYMPI). Pain 23:345–356PubMedCrossRef
17.
Laliberté S, Sullivan MJL, Charron JLJ, Bouthiller D, Miller J-M, Tremblay I (2005) Du Multidimensional Pain Inventory à l’inventaire multidimensionnel de la douleur : traduction et validation. Canadian Pain Society Meeting (abstract)
18.
19.
Leplege A, Ecosse E, Verdier A, Perneger TV (1998) The French SF-36 Health Survey: translation, cultural adaptation and preliminary psychometric evaluation. J Clin Epidemiol 51:1013–1023PubMedCrossRef
20.
Sullivan MJL, Bishop S, Pivik J (1995) The pain catastrophizing scale: development and validation. Psychol Assess 7:524–532CrossRef
21.
French DJ, Noel M, Vigneau F, French JA, Cyr CP, Evans RT (2005) L’Échelle de dramatisation face à la douleur PCS-CF Adaptation canadienne en langue française de l’échelle «Pain Catastrophizing Scale». Revue canadienne des sciences du comportement 37:181–192CrossRef
22.
Marchand S, Arsenault P (2002) Spatial summation for pain perception: interaction of inhibitory and excitatory mechanisms. Pain 95:201–206PubMedCrossRef
23.
Marchand S, Charest J, Li J, Chenard JR, Lavignolle B, Laurencelle L (1993) Is TENS purely a placebo effect? A controlled study on chronic low back pain. Pain 54:99–106PubMedCrossRef
24.
Aldenderfer MS, Blashfield RK (1984) Cluster analysis. Sage Press, Beverly Hills
25.
Milligan GW, Cooper MC (1985) An examination of procedures for determining the number of clusters in a data set. Psychometrika 50:159–179CrossRef
26.
Kosek E, Ekholm J, Hansson P (1996) Sensory dysfunction in fibromyalgia patients with implications for pathogenic mechanisms. Pain 68:375–383PubMedCrossRef
27.
Julien N, Goffaux P, Arsenault P, Marchand S (2005) Widespread pain in fibromyalgia is related to a deficit of endogenous pain inhibition. Pain 114:295–302PubMedCrossRef
28.
Lowe B, Grafe K, Ufer C et al (2004) Anxiety and depression in patients with pulmonary hypertension. Psychosom Med 66:831–836PubMedCrossRef
29.
Barth J, Schumacher M, Herrmann-Lingen C (2004) Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. Psychosom Med 66:802–813PubMedCrossRef
30.
Maddigan SL, Feeny DH, Majumdar SR, Farris KB, Johnson JA (2006) Understanding the determinants of health for people with type 2 diabetes. Am J Public Health 96:1649–1655PubMedCrossRef
Metadata
Title
Fibromyalgia subgroups: profiling distinct subgroups using the Fibromyalgia Impact Questionnaire. A preliminary study
Authors
Juliana Barcellos de Souza
Philippe Goffaux
Nancy Julien
Stephane Potvin
Jacques Charest
Serge Marchand
Publication date
01-03-2009
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 5/2009
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-008-0722-5

Other articles of this Issue 5/2009

Rheumatology International 5/2009 Go to the issue

Original Article

Less disease severity and favorable prognosis are associated with postmenopausal systemic lupus erythematosus patients

Case Report

Anasarca as the presenting manifestation of parvovirus B19 associated juvenile dermatomyositis

Original Article

Risk factors of Pneumocystis jeroveci pneumonia in patients with systemic lupus erythematosus

Short Communication

Behçet’s disease: clinical value of the video capsule endoscopy for small intestine examination

Letter to the Editor

Serum and bronchoalveolar lavage fluid nitric oxide levels in diffuse systemic sclerosis

Case Report

Rheumatoid cranial pachymeningitis successfully treated with long-term corticosteroid
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits